BMY stock has seen a 23% rise YTD, outperforming its peers and the broader markets, primarily due to an increase in dividends and boosting its share repurchase program.
A box of Bristol-Myers Squibb Co. Eliquis tablets are arranged for a photograph at a pharmacy in … [+] Princeton, Illinois, U.S., on Monday, Jan. 7, 2019. Photographer: Daniel Acker/Bloomberg © 2019 Bloomberg Finance LP
Bristol Myers Squibb (NYSE: BMY) is scheduled to report its Q1 2023 results on Friday, April 29. We expect BMS to report revenue and earnings above the consensus estimates. Market share gains for Eliquis, Opdivo, and Reblozyl likely drove BMS’ sales growth. BMY stock has seen a 23% rise YTD, outperforming its peers and the broader markets, primarily due to an increase in dividends and boosting its share repurchase program.
